{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T20:46:38Z","timestamp":1795293998395,"version":"4.10.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["ig19991"],"award-info":[{"award-number":["ig19991"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007479","name":"Fondazione Cassa di Risparmio di Padova e Rovigo","doi-asserted-by":"publisher","award":["SIGMI"],"award-info":[{"award-number":["SIGMI"]}],"id":[{"id":"10.13039\/100007479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017BF3PXZ"],"award-info":[{"award-number":["2017BF3PXZ"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mitochondrial fusion and fission proteins have been nominated as druggable targets in cancer. Whether their inhibition is efficacious in triple negative breast cancer (TNBC) that almost invariably develops chemoresistance is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used a combination of bioinformatics analyses of cancer genomic databases, genetic and pharmacological Optic Atrophy 1 (OPA1) inhibition, mitochondrial function and morphology measurements, micro-RNA (miRNA) profiling and formal epistatic analyses to address the role of OPA1 in TNBC proliferation, migration, and invasion in vitro and in vivo<jats:italic>.<\/jats:italic><\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified a signature of OPA1 upregulation in breast cancer that correlates with worse prognosis. Accordingly, OPA1 inhibition could reduce breast cancer cells proliferation, migration, and invasion in vitro and in vivo. Mechanistically, while OPA1 silencing did not reduce mitochondrial respiration, it increased levels of miRNAs of the 148\/152 family known to inhibit tumor growth and invasiveness. Indeed, these miRNAs were epistatic to <jats:italic>OPA1<\/jats:italic> in the regulation of TNBC cells growth and invasiveness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data show that targeted inhibition of the mitochondrial fusion protein OPA1 curtails TNBC growth and nominate OPA1 as a druggable target in TNBC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-022-02304-6","type":"journal-article","created":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T08:05:48Z","timestamp":1647072348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth"],"prefix":"10.1186","volume":"41","author":[{"given":"Margherita","family":"Zamberlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Boeckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Vinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Coart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Grespi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Giacomello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Struman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8515-8928","authenticated-orcid":false,"given":"Luca","family":"Scorrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Herkenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"key":"2304_CR1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/cancers12040916","volume":"12","author":"E Vagia","year":"2020","unstructured":"Vagia E, Mahalingam D, Cristofanilli M. The Landscape of Targeted Therapies in TNBC. Cancers. 2020;12:916.","journal-title":"Cancers"},{"key":"2304_CR2","doi-asserted-by":"publisher","unstructured":"Yedjou CG, Sims J, Miele L. Health and racial disparity in breast cancer. https:\/\/doi.org\/10.1007\/978-3-030-20301-6_3.","DOI":"10.1007\/978-3-030-20301-6_3"},{"key":"2304_CR3","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"2304_CR4","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688\u201398.","journal-title":"Clin Cancer Res"},{"key":"2304_CR5","doi-asserted-by":"crossref","unstructured":"Liu YR, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res. 2016;18(1):338.","DOI":"10.1186\/s13058-016-0690-8"},{"key":"2304_CR6","doi-asserted-by":"crossref","unstructured":"Diana A, et al. Triple-negative breast cancers: systematic review of the literature on molecular and clinical features with a focus on treatment with innovative drugs. Curr Oncol Rep. 2018 Aug 20;20(10):76.","DOI":"10.1007\/s11912-018-0726-6"},{"key":"2304_CR7","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/tbj.13946","volume":"26","author":"A Puri","year":"2020","unstructured":"Puri A, Reddy TP, Patel TA, Chang JC. Metastatic triple-negative breast cancer: Established and emerging treatments. Breast J. 2020;26:1793\u20136.","journal-title":"Breast J"},{"key":"2304_CR8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361\u201370.","journal-title":"Cancer Immunol Res"},{"key":"2304_CR9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s13304-017-0424-1","volume":"69","author":"Z Anastasiadi","year":"2017","unstructured":"Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M. Breast cancer in young women: an overview. Updates Surg. 2017;69:313\u20137.","journal-title":"Updates Surg"},{"key":"2304_CR10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of Cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"2304_CR11","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","volume":"24","author":"A Luengo","year":"2017","unstructured":"Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chem Biol. 2017;24:1161\u201380.","journal-title":"Cell Chem Biol"},{"key":"2304_CR12","doi-asserted-by":"crossref","unstructured":"RJ DB, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.","DOI":"10.1126\/sciadv.1600200"},{"key":"2304_CR13","doi-asserted-by":"crossref","unstructured":"Sun X, et al. Metabolic reprogramming in triple-negative breast cancer. Front Oncol. 2020;10:428.","DOI":"10.3389\/fonc.2020.00428"},{"key":"2304_CR14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.tcb.2010.03.002","volume":"20","author":"SF Funderburk","year":"2010","unstructured":"Funderburk SF, Wang QJ, Yue Z. The Beclin 1-VPS34 complex--at the crossroads of autophagy and beyond. Trends Cell Biol. 2010;20:355\u201362.","journal-title":"Trends Cell Biol"},{"key":"2304_CR15","doi-asserted-by":"crossref","unstructured":"Reda A, et al. Role of mitochondria in rescuing glycolytically inhibited subpopulation of triple negative but not hormone-responsive breast cancer cells. Sci Rep. 2019;9(1):13748.","DOI":"10.1038\/s41598-019-50141-z"},{"key":"2304_CR16","doi-asserted-by":"crossref","unstructured":"Lanning NJ, et al. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities. Cancer Metab. 2017;5:6.","DOI":"10.1186\/s40170-017-0168-x"},{"key":"2304_CR17","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/ncb3039","volume":"16","author":"VS LeBleu","year":"2014","unstructured":"LeBleu VS, et al. PGC-1\u03b1 mediates mitochondrial biogenesis and oxidative phosphorylation to promote metastasis. Nat Cell Biol. 2014;16:992.","journal-title":"Nat Cell Biol"},{"key":"2304_CR18","first-page":"1189","volume":"8","author":"LR Cavalli","year":"1997","unstructured":"Cavalli LR, Varella-Garcia M, Liang BC. Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ. 1997;8:1189\u201398.","journal-title":"Cell Growth Differ"},{"key":"2304_CR19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-physiol-021115-105011","volume":"78","author":"L Pernas","year":"2016","unstructured":"Pernas L, Scorrano L. Mito-Morphosis: mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function. Annu Rev Physiol. 2016;78:505\u201331.","journal-title":"Annu Rev Physiol"},{"key":"2304_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1083\/jcb.200211046","volume":"160","author":"H Chen","year":"2003","unstructured":"Chen H, et al. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003;160:189\u2013200.","journal-title":"J Cell Biol"},{"key":"2304_CR21","doi-asserted-by":"crossref","first-page":"15927","DOI":"10.1073\/pnas.0407043101","volume":"101","author":"S Cipolat","year":"2004","unstructured":"Cipolat S, De Brito OM, Dal Zilio B, Scorrano L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci U S A. 2004;101:15927\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2304_CR22","doi-asserted-by":"crossref","first-page":"20931","DOI":"10.18632\/aging.104207","volume":"12","author":"S Herkenne","year":"2020","unstructured":"Herkenne S, Scorrano L. OPA1, a new mitochondrial target in cancer therapy. Aging (Albany NY). 2020;12:20931\u20133.","journal-title":"Aging (Albany NY)"},{"key":"2304_CR23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2013.08.032","volume":"155","author":"S Cogliati","year":"2013","unstructured":"Cogliati S, et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell. 2013;155:160\u201371.","journal-title":"Cell"},{"key":"2304_CR24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cell.2006.06.025","volume":"126","author":"C Frezza","year":"2006","unstructured":"Frezza C, et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell. 2006;126:177\u201389.","journal-title":"Cell"},{"key":"2304_CR25","doi-asserted-by":"crossref","unstructured":"Anderson GR, et al. Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors. Nat Commun. 2018;9.","DOI":"10.1038\/s41467-018-04033-x"},{"key":"2304_CR26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.humpath.2011.04.012","volume":"43","author":"HY Fang","year":"2012","unstructured":"Fang HY, et al. Overexpression of optic atrophy 1 protein increases cisplatin resistance via inactivation of caspase-dependent apoptosis in lung adenocarcinoma cells. Hum Pathol. 2012;43:105\u201314.","journal-title":"Hum Pathol"},{"key":"2304_CR27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/labinvest.2012.144","volume":"93","author":"X Zhao","year":"2013","unstructured":"Zhao X, et al. OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma. Lab Investig. 2013;93:8\u201319.","journal-title":"Lab Investig"},{"key":"2304_CR28","doi-asserted-by":"crossref","first-page":"27134","DOI":"10.1074\/jbc.M114.594812","volume":"289","author":"B Kong","year":"2014","unstructured":"Kong B, Wang Q, Fung E, Xue K, Tsang BK. P53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers. J Biol Chem. 2014;289:27134\u201345.","journal-title":"J Biol Chem"},{"key":"2304_CR29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019;9:890\u2013909.","journal-title":"Cancer Discov"},{"key":"2304_CR30","doi-asserted-by":"crossref","unstructured":"Betancur, J. G., et al. miRNA-like duplexes as RNAi triggers with improved specificity. 2012;3:127.","DOI":"10.3389\/fgene.2012.00127"},{"key":"2304_CR31","doi-asserted-by":"crossref","unstructured":"Correa de Sampaio P, et al. A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. Plos One. 2012;7(2):e30753.","DOI":"10.1371\/journal.pone.0030753"},{"key":"2304_CR32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"2304_CR33","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1096\/fj.201901467R","volume":"34","author":"D Wu","year":"2020","unstructured":"Wu D, et al. Identification of novel dynamin-related protein 1 (Drp1) GTPase inhibitors: Therapeutic potential of Drpitor1 and Drpitor1a in cancer and cardiac ischemia-reperfusion injury. FASEB J. 2020;34:1447\u201364.","journal-title":"FASEB J"},{"key":"2304_CR34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amsu.2016.01.091","volume":"7","author":"W None","year":"2016","unstructured":"None W, Djati MS, Rifa'i M. Role of MicroRNAs in carcinogenesis that potential for biomarker of endometrial cancer. Ann Med Surg. 2016;7:9\u201313.","journal-title":"Ann Med Surg"},{"key":"2304_CR35","doi-asserted-by":"crossref","unstructured":"Loh HY, et al. The regulatory role of MicroRNAs in breast cancer. Int J Mol Sci. 2019;20(19):4940.","DOI":"10.3390\/ijms20194940"},{"key":"2304_CR36","doi-asserted-by":"publisher","unstructured":"Mcguire A, Brown JAL, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. 2015. https:\/\/doi.org\/10.1007\/s10555-015-9551-7.","DOI":"10.1007\/s10555-015-9551-7"},{"key":"2304_CR37","first-page":"1","volume":"8","author":"Y Wee","year":"2018","unstructured":"Wee Y, Liu Y, Lu J, Li X, Zhao M. Identification of novel prognosis-related genes associated with cancer using integrative network analysis. Sci Rep. 2018;8:1\u201311.","journal-title":"Sci Rep"},{"key":"2304_CR38","doi-asserted-by":"crossref","first-page":"18792","DOI":"10.1074\/jbc.M400920200","volume":"279","author":"L Griparic","year":"2004","unstructured":"Griparic L, Van Der Wel NN, Orozco IJ, Peters PJ, Van Der Bliek AM. Loss of the intermembrane space protein Mgm1\/OPA1 induces swelling and localized constrictions along the lengths of mitochondria. J Biol Chem. 2004;279:18792\u20138.","journal-title":"J Biol Chem"},{"key":"2304_CR39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2020.04.007","volume":"31","author":"S Herkenne","year":"2020","unstructured":"Herkenne S, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020;31:987\u20131003.e8.","journal-title":"Cell Metab"},{"key":"2304_CR40","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/s41418-021-00747-6","volume":"28","author":"M Corrado","year":"2021","unstructured":"Corrado M, et al. Deletion of the mitochondria-shaping protein Opa1 during early thymocyte maturation impacts mature memory T cell metabolism. Cell Death Differ. 2021;28:2194\u2013206.","journal-title":"Cell Death Differ"},{"issue":"10","key":"2304_CR41","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1074\/jbc.C200677200","volume":"278","author":"A Olichon","year":"2003","unstructured":"Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P, et al. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem. 2003;278(10):7743\u20136.","journal-title":"J Biol Chem"},{"issue":"1","key":"2304_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0930-x","volume":"12","author":"Y Chen","year":"2013","unstructured":"Chen Y, Song Y-X, Wang Z-N. The MicroRNA-148\/152 family: multi-faceted players. Mol Cancer. 2013;12(1):1\u20138.","journal-title":"Mol Cancer"},{"key":"2304_CR43","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s13277-015-3926-9","volume":"37","author":"J Xue","year":"2016","unstructured":"Xue J, Chen Z, Gu X, Zhang Y, Zhang W. MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13. Tumour Biol. 2016;37:1581\u201390.","journal-title":"Tumour Biol"},{"key":"2304_CR44","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3892\/or.2015.4502","volume":"35","author":"Q Jiang","year":"2016","unstructured":"Jiang Q, et al. MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1. Oncol Rep. 2016;35:1425\u201332.","journal-title":"Oncol Rep"},{"key":"2304_CR45","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s11605-010-1202-2","volume":"14","author":"Y Chen","year":"2010","unstructured":"Chen Y, et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010;14:1170\u20139.","journal-title":"J Gastrointest Surg"},{"key":"2304_CR46","unstructured":"Zhang L, Xing M, Wang X, Cao W, Wang H. MiR-148a suppresses invasion and induces apoptosis of breast cancer cells by regulating USP4 and BIM expression. Int J Clin Exp Pathol. 2017;10(8):8361\u20138."},{"key":"2304_CR47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2119\/molmed.2010.00239","volume":"17","author":"W Pavicic","year":"2011","unstructured":"Pavicic W, Perkio E, Kaur S, Peltomaki P. Altered methylation at microRNA-associated CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)-based approach. Mol Med. 2011;17:726\u201335.","journal-title":"Mol Med"},{"key":"2304_CR48","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s12032-011-0134-3","volume":"29","author":"A Zhu","year":"2012","unstructured":"Zhu A, et al. MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer. Med Oncol. 2012;29:2701\u20139.","journal-title":"Med Oncol"},{"key":"2304_CR49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jmcb\/mjs049","volume":"5","author":"Q Xu","year":"2013","unstructured":"Xu Q, et al. A regulatory circuit of miR-148a\/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 2013;5:3\u201313.","journal-title":"J Mol Cell Biol"},{"key":"2304_CR50","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1373\/clinchem.2010.144709","volume":"56","author":"N Hanoun","year":"2010","unstructured":"Hanoun N, et al. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem. 2010;56:1107\u201318.","journal-title":"Clin Chem"},{"key":"2304_CR51","first-page":"447","volume":"27","author":"X Zhou","year":"2012","unstructured":"Zhou X, et al. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep. 2012;27:447\u201354.","journal-title":"Oncol Rep"},{"key":"2304_CR52","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1007\/s13277-015-4340-z","volume":"37","author":"F Wang","year":"2016","unstructured":"Wang F, et al. Circulating miR-148\/152 family as potential biomarkers in hepatocellular carcinoma. Tumour Biol. 2016;37:4945\u201353.","journal-title":"Tumour Biol"},{"key":"2304_CR53","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.445585","volume-title":"DNA 5-Methylcytosine demethylation activities of the mammalian DNA methyltransferases * \u25a1 S","author":"C-C Chen","year":"2013","unstructured":"Chen C-C, Wang K-Y, James Shen C-K. DNA 5-Methylcytosine demethylation activities of the mammalian DNA methyltransferases * \u25a1 S; 2013. https:\/\/doi.org\/10.1074\/jbc.M112.445585."},{"issue":"1","key":"2304_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-29972-9","volume":"8","author":"C Bocca","year":"2018","unstructured":"Bocca C, et al. The metabolomic bioenergetic signature of opa1-disrupted mouse embryonic fibroblasts highlights aspartate deficiency. Sci Rep. 2018;8(1):1\u201311.","journal-title":"Sci Rep"},{"key":"2304_CR55","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature19353","volume":"537","author":"M Sciacovelli","year":"2016","unstructured":"Sciacovelli M, et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition Europe PMC funders group. Nature. 2016;537:544\u20137.","journal-title":"Nature"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02304-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02304-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02304-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T08:08:09Z","timestamp":1647072489000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02304-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2304"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02304-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,12]]},"assertion":[{"value":"31 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All in vivo experiments were approved by the local Animal Ethic Commission (File number 2166, \u201cCommission d\u2019\u00e9thique de l\u2019utilisation des animaux de l\u2019Universit\u00e9 de Li\u00e8ge\u201d).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LS is an inventor in the PCT\/EP2019\/068846 on MYLS22 as an anticancer drug. All other authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}